Terazosin Capsule
Product Images NDC 69452-331

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 69452-331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Figure 01)

This text provides information on the mean change in total symptom score and the mean increase in peak flow rate (mL/sec) from baseline between the placebo and terazosin groups in a study. The study includes 54 participants and is represented graphically in Figure 1. Additionally, the data is presented over a 3-month period.*

FDA Label Image

Image Description (Figure 02)

This is a figure showing the mean change in total symptom score from baseline in a long-term, open-label study with 494 participants. The data is presented for different time points up to 30 months.*

FDA Label Image

Image Description (Figure 03)

This information shows the mean change in peak flow rate from the baseline in a Long-Term, Open-Label, Non-Placebo Controlled Study involving 494 participants. The data is presented in a graphical format depicting the change in milliliters per second over a period of 30 months.*

FDA Label Image

Image Description (Image001)

This is a description of Terazosin capsules, a prescription medication containing terazosin hydrochloride, USP equivalent to 1mg of terazosin. The usual dosage information is included in the package insert. The capsules should be stored in a tight, light-resistant container at temperatures between 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). It is essential to protect the capsules from light and moisture. These capsules are distributed by Bionpharma Inc. in Princeton, NJ, and are manufactured in India. Additional codes and identification numbers are listed for tracking purposes.*

FDA Label Image

Image Description (Image002)

This text provides information about Terazosin capsules, USP with each capsule containing Terazosin hydrochloride equivalent to 2 mg of Terazosin. It includes instructions for usual dosage, storage conditions, and the manufacturer details. The capsules should be dispensed in a tight, light-resistant container and protected from light and moisture. The product is distributed by Bionpharma Inc. in Princeton, NJ, and the manufacturing is done in India.*

FDA Label Image

Image Description (Image003)

This is a description of Terazosin capsules, each containing 5 mg of Terazosin hydrochloride, USP. The usual dosage instructions are provided in the package insert. The capsules should be stored in a tight, light-resistant container at a temperature between 20°C to 25°C (68°F to 77°F), with permitted excursions to 16°C to 30°C (59°F to 86°F). It is essential to protect the capsules from light and moisture. The product is distributed by Bionpharma Inc. and manufactured in India.*

FDA Label Image

Image Description (Image004)

This text is a detailed description of Terazosin capsules, a prescription medication containing 10mg of Terazosin hydrochloride. It includes storage instructions, prescribing information, and details of the manufacturer, Bionpharma Inc. The medication is distributed in tight, light-resistant containers to protect it from light and moisture. The text also provides the NDC, Rx only label, dosage information, and the capsule count in the package.*

FDA Label Image

Image Description (Structure001)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.